Akebia Therapeutics, Inc.盘中异动大幅下挫5.10%

市场透视2025-05-12

北京时间2025年05月12日21时38分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速下挫5.10%。截至发稿，该股报2.42美元/股，成交量78.6746万股，换手率0.30%，振幅5.49%。最近的财报数据显示，该股实现营业收入57.34百万美元，净利润6.11百万美元，每股收益0.03美元，毛利49.40百万美元，市盈率-11.52倍。机构评级...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2534620834?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-12 21:38","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2534620834","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics, Inc.盘中异动 大幅下挫5.10%","media":"市场透视","content":"<div>\n<p>北京时间2025年05月12日21时38分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速下挫5.10%。截至发稿，该股报2.42美元/股，成交量78.6746万股，换手率0.30%，振幅5.49%。最近的财报数据显示，该股实现营业收入57.34百万美元，净利润6.11百万美元，每股收益0.03美元，毛利49.40百万美元，市盈率-11.52倍。机构评级...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213843aa2c8b2f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics, Inc.盘中异动 大幅下挫5.10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics, Inc.盘中异动 大幅下挫5.10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-12 21:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213843aa2c8b2f&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2025年05月12日21时38分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速下挫5.10%。截至发稿，该股报2.42美元/股，成交量78.6746万股，换手率0.30%，振幅5.49%。最近的财报数据显示，该股实现营业收入57.34百万美元，净利润6.11百万美元，每股收益0.03美元，毛利49.40百万美元，市盈率-11.52倍。机构评级...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213843aa2c8b2f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213843aa2c8b2f&s=b","article_id":"2534620834","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512213843aa2c8b2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2534620834","pubTimestamp":1747057123,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2025年05月12日21时38分，Akebia Therapeutics, Inc.股票出现异动，股价快速下挫5.10%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.64%。其相关个股中，脑再生科技、Medicus Pharma Ltd.、坎伯兰药业涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Petros Pharmaceuticals, Inc.、Incannex Healthcare Inc.较为活跃，换手率分别为188.48%、76.95%、6.29%，振幅较大的相关个股有脑再生科技、Incannex Healthcare Inc.、Medicus Pharma Ltd.，振幅分别为13.54%、12.78%、10.89%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","BK4007":"制药","AKBA":"Akebia Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"Akebia Therapeutics, Inc. Down 5.10% Intraday Movement","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1,"LENZ":1},"content_text":"北京时间2025年05月12日21时38分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速下挫5.10%。截至发稿，该股报2.42美元/股，成交量78.6746万股，换手率0.30%，振幅5.49%。最近的财报数据显示，该股实现营业收入57.34百万美元，净利润6.11百万美元，每股收益0.03美元，毛利49.40百万美元，市盈率-11.52倍。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Akebia Therapeutics, Inc.股票所在的制药行业中，整体涨幅为0.64%。其相关个股中，脑再生科技、Medicus Pharma Ltd.、坎伯兰药业涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Petros Pharmaceuticals, Inc.、Incannex Healthcare Inc.较为活跃，换手率分别为188.48%、76.95%、6.29%，振幅较大的相关个股有脑再生科技、Incannex Healthcare Inc.、Medicus Pharma Ltd.，振幅分别为13.54%、12.78%、10.89%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。该公司的经营部门是开发和商业化用于肾脏疾病患者的新疗法。该公司目前的产品组合包括Auryxia(铁柠檬酸盐)，一种在美国批准并上市的药物，用于控制透析依赖性慢性肾病成人患者的血清磷水平和治疗缺铁性贫血，用于非透析依赖性慢性肾病成人患者，Vafseo (vadadustat)，一种口服缺氧诱导因子脯氨酰羟化酶抑制剂。HIF-PH抑制剂在日本被批准用于治疗成人慢性肾脏疾病引起的贫血，处于临床前开发阶段。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2534620834","isCrawlerRequest":true}

Akebia Therapeutics, Inc.盘中异动 大幅下挫5.10%

精彩评论

Akebia Therapeutics, Inc.盘中异动大幅下挫5.10%